MIG Polyclonal antibody

MIG Polyclonal Antibody for IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, IHC, ELISA

Conjugate

Unconjugated

Cat no : 22355-1-AP

Synonyms

C X C motif chemokine 9, CMK, crg 10, CXCL9, Humig, MIG, MIG; CXCL9, SCYB9, Small inducible cytokine B9



Tested Applications

Positive IHC detected inhuman colon cancer tissue, human lung cancer tissue, human tonsillitis tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Immunohistochemistry (IHC)IHC : 1:50-1:500
Sample-dependent, check data in validation data gallery

Product Information

The immunogen of 22355-1-AP is MIG Fusion Protein expressed in E. coli.

Tested Reactivity human, mouse
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen MIG fusion protein Ag17932
Full Name chemokine (C-X-C motif) ligand 9
Calculated molecular weight 14 kDa
GenBank accession numberBC095396
Gene symbol CXCL9
Gene ID (NCBI) 4283
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

CXCL9 is a small cytokine known as MIG. CXCL9 is a T-cell chemoattractant, which is induced by IFN-γ. It is closely related to two other CXC chemokines called CXCL10 and CXCL11, whose genes are located near the gene for CXCL9 on human chromosome 4. A high level of CXCL9 revealed in peripheral liquids, can be considered as a marker of host immune response, especially of that involving Th1 cells.

Protocols

Product Specific Protocols
IHC protocol for MIG antibody 22355-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanIHC

Front Immunol

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer.

Authors - Chengming Liu
humanIHC

Cancer Cell Int

Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma.

Authors - Wenqin Feng
humanIHC

J Plast Surg Hand Surg

A comparison expression analysis of CXCR4, CXCL9 and Caspase-9 in dermal vascular endothelial cells between keloids and normal skin on chemotaxis and apoptosis.

Authors - Xinhang Dong
humanWB,IHC

Cancer Immunol Immunother

CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer

Authors - Lei Wu